Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations
Identifieur interne : 003976 ( Istex/Corpus ); précédent : 003975; suivant : 003977Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations
Auteurs : Yoshiaki Furukawa ; James J. Filiano ; Stephen J. KishSource :
- Movement Disorders [ 0885-3185 ] ; 2004-10.
English descriptors
Abstract
Amantadine suppressed severe levodopa‐induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine‐deficient metabolic disorders. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20194
Links to Exploration step
ISTEX:19E87E9E42A5799A024DE5A9F3F2BA61D713A376Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations</title><author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name><affiliation><mods:affiliation>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health‐Clarke Division, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Filiano, James J" sort="Filiano, James J" uniqKey="Filiano J" first="James J." last="Filiano">James J. Filiano</name><affiliation><mods:affiliation>Department of Pediatrics/Neurology, Dartmouth–Hitchcock Medical Center, Lebanon, New Hampshire, USA</mods:affiliation></affiliation></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><affiliation><mods:affiliation>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health—Clarke Division, Toronto, Ontario, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:19E87E9E42A5799A024DE5A9F3F2BA61D713A376</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20194</idno><idno type="url">https://api.istex.fr/document/19E87E9E42A5799A024DE5A9F3F2BA61D713A376/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003976</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations</title><author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name><affiliation><mods:affiliation>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health‐Clarke Division, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Filiano, James J" sort="Filiano, James J" uniqKey="Filiano J" first="James J." last="Filiano">James J. Filiano</name><affiliation><mods:affiliation>Department of Pediatrics/Neurology, Dartmouth–Hitchcock Medical Center, Lebanon, New Hampshire, USA</mods:affiliation></affiliation></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><affiliation><mods:affiliation>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health—Clarke Division, Toronto, Ontario, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-10">2004-10</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1256">1256</biblScope><biblScope unit="page" to="1258">1258</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">19E87E9E42A5799A024DE5A9F3F2BA61D713A376</idno><idno type="DOI">10.1002/mds.20194</idno><idno type="ArticleID">MDS20194</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>GTP cyclohydrolase I deficiency</term><term>amantadine</term><term>levodopa‐induced dyskinesias</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Amantadine suppressed severe levodopa‐induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine‐deficient metabolic disorders. © 2004 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Yoshiaki Furukawa MD</name><affiliations><json:string>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health‐Clarke Division, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>James J. Filiano MD</name><affiliations><json:string>Department of Pediatrics/Neurology, Dartmouth–Hitchcock Medical Center, Lebanon, New Hampshire, USA</json:string></affiliations></json:item><json:item><name>Stephen J. Kish PhD</name><affiliations><json:string>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health—Clarke Division, Toronto, Ontario, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>amantadine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa‐induced dyskinesias</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>GTP cyclohydrolase I deficiency</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Amantadine suppressed severe levodopa‐induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine‐deficient metabolic disorders. © 2004 Movement Disorder Society</abstract><qualityIndicators><score>2.318</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>459</abstractCharCount><pdfWordCount>1610</pdfWordCount><pdfCharCount>11205</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>59</abstractWordCount></qualityIndicators><title>Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations</title><genre><json:string>Serial article</json:string></genre><host><volume>19</volume><pages><total>2</total><last>1258</last><first>1256</first></pages><issn><json:string>0885-3185</json:string></issn><issue>10</issue><subject><json:item><value>Clinical/Scientific Note</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1002/mds.20194</json:string></doi><id>19E87E9E42A5799A024DE5A9F3F2BA61D713A376</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/19E87E9E42A5799A024DE5A9F3F2BA61D713A376/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/19E87E9E42A5799A024DE5A9F3F2BA61D713A376/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/19E87E9E42A5799A024DE5A9F3F2BA61D713A376/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2004</date></publicationStmt><notesStmt><note>Centre for Addiction and Mental Health Foundation</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations</title><author><persName><forename type="first">Yoshiaki</forename><surname>Furukawa</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Movement Disorders Research Laboratory, Centre for Addiction and Mental Health—Clarke Division, 250 College Street, Toronto, Ontario M5T 1R8, Canada</p></note><affiliation>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health‐Clarke Division, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">James J.</forename><surname>Filiano</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Pediatrics/Neurology, Dartmouth–Hitchcock Medical Center, Lebanon, New Hampshire, USA</affiliation></author><author><persName><forename type="first">Stephen J.</forename><surname>Kish</surname><roleName type="degree">PhD</roleName></persName><affiliation>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health—Clarke Division, Toronto, Ontario, Canada</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-10"></date><biblScope unit="vol">19</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1256">1256</biblScope><biblScope unit="page" to="1258">1258</biblScope></imprint></monogr><idno type="istex">19E87E9E42A5799A024DE5A9F3F2BA61D713A376</idno><idno type="DOI">10.1002/mds.20194</idno><idno type="ArticleID">MDS20194</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Amantadine suppressed severe levodopa‐induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine‐deficient metabolic disorders. © 2004 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>amantadine</term></item><item><term>levodopa‐induced dyskinesias</term></item><item><term>GTP cyclohydrolase I deficiency</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Clinical/Scientific Note</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2003-09-22">Received</change><change when="2004-03-22">Registration</change><change when="2004-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/19E87E9E42A5799A024DE5A9F3F2BA61D713A376/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley" registered="yes">10.1002/mds.v19:10</doi><numberingGroup><numbering type="journalVolume" number="19">19</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2004-10">October 2004</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="260" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20194</doi><idGroup><id type="unit" value="MDS20194"></id></idGroup><countGroup><count type="pageTotal" number="2"></count></countGroup><titleGroup><title type="articleCategory">Clinical/Scientific Note</title><title type="tocHeading1">Clinical/Scientific Notes</title></titleGroup><copyright ownership="thirdParty">Copyright © 2004 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2003-09-22"></event><event type="manuscriptAccepted" date="2004-03-22"></event><event type="publishedOnlineEarlyUnpaginated" date="2004-06-10"></event><event type="firstOnline" date="2004-06-10"></event><event type="publishedOnlineFinalForm" date="2004-09-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1256</numbering><numbering type="pageLast">1258</numbering></numberingGroup><correspondenceTo>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health—Clarke Division, 250 College Street, Toronto, Ontario M5T 1R8, Canada</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20194.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="15"></count><count type="wordTotal" number="1653"></count></countGroup><titleGroup><title type="main" xml:lang="en">Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for <i>GCH1</i> mutations</title><title type="short" xml:lang="en">Clinical/Scientific Notes</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Yoshiaki</givenNames><familyName>Furukawa</familyName><degrees>MD</degrees></personName><contactDetails><email>yoshiaki_furukawa@camh.net</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>James J.</givenNames><familyName>Filiano</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Stephen J.</givenNames><familyName>Kish</familyName><degrees>PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CA" type="organization"><unparsedAffiliation>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health‐Clarke Division, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Pediatrics/Neurology, Dartmouth–Hitchcock Medical Center, Lebanon, New Hampshire, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="CA" type="organization"><unparsedAffiliation>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health—Clarke Division, Toronto, Ontario, Canada</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">amantadine</keyword><keyword xml:id="kwd2">levodopa‐induced dyskinesias</keyword><keyword xml:id="kwd3">GTP cyclohydrolase I deficiency</keyword></keywordGroup><fundingInfo><fundingAgency>Centre for Addiction and Mental Health Foundation</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Amantadine suppressed severe levodopa‐induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous <i>GCH1</i> mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine‐deficient metabolic disorders. © 2004 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Clinical/Scientific Notes</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for</title></titleInfo><name type="personal"><namePart type="given">Yoshiaki</namePart><namePart type="family">Furukawa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health‐Clarke Division, Toronto, Ontario, Canada</affiliation><description>Correspondence: Movement Disorders Research Laboratory, Centre for Addiction and Mental Health—Clarke Division, 250 College Street, Toronto, Ontario M5T 1R8, Canada</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">James J.</namePart><namePart type="family">Filiano</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Pediatrics/Neurology, Dartmouth–Hitchcock Medical Center, Lebanon, New Hampshire, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephen J.</namePart><namePart type="family">Kish</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health—Clarke Division, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">shortCommunication</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2004-10</dateIssued><dateCaptured encoding="w3cdtf">2003-09-22</dateCaptured><dateValid encoding="w3cdtf">2004-03-22</dateValid><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="references">15</extent><extent unit="words">1653</extent></physicalDescription><abstract lang="en">Amantadine suppressed severe levodopa‐induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine‐deficient metabolic disorders. © 2004 Movement Disorder Society</abstract><note type="funding">Centre for Addiction and Mental Health Foundation</note><subject lang="en"><genre>Keywords</genre><topic>amantadine</topic><topic>levodopa‐induced dyskinesias</topic><topic>GTP cyclohydrolase I deficiency</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Clinical/Scientific Note</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1256</start><end>1258</end><total>2</total></extent></part></relatedItem><identifier type="istex">19E87E9E42A5799A024DE5A9F3F2BA61D713A376</identifier><identifier type="DOI">10.1002/mds.20194</identifier><identifier type="ArticleID">MDS20194</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003976 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003976 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:19E87E9E42A5799A024DE5A9F3F2BA61D713A376
|texte= Amantadine for levodopa‐induced choreic dyskinesia in compound heterozygotes for GCH1 mutations
}}
| This area was generated with Dilib version V0.6.23. |  |